Vera Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain
Vera Therapeutics, Inc. (VERA) reported Debt Securities, Available-for-sale, Unrealized Gain of $810.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2026-02-26
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-12-31 was -$85.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-09-30 was $323.00K, a 67.64% decline year-over-year.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-06-30 was -$119.00K.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-03-31 was $691.00K, a 619.79% increase year-over-year.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for fiscal 2025 was $810.00K, a 41.61% increase from fiscal 2024.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for fiscal 2024 was $572.00K, a 111.07% increase from fiscal 2023.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for fiscal 2023 was $271.00K, a 27000.00% increase from fiscal 2022.
- Vera Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for fiscal 2022 was $1.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $238.00K derived: sum of 2 quarters · filed 2026-02-26 | $119.00K derived: sum of 3 quarters · filed 2026-02-26 | $810.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $323.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $204.00K derived: sum of 2 quarters · filed 2025-11-05 | $895.00K 10-Q · filed 2025-11-05 | $423.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | -$119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $572.00K 10-Q · filed 2025-08-05 | $100.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $691.00K 10-Q · filed 2025-05-07 | $219.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.22M derived: sum of 3 quarters · filed 2026-02-26 | $1.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | -$472.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $526.00K derived: sum of 2 quarters · filed 2026-02-26 | $476.00K derived: sum of 3 quarters · filed 2026-02-26 | $572.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $998.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $948.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.04M 10-Q · filed 2024-11-07 | $1.31M derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $46.00K 10-Q · filed 2024-08-08 | $315.00K derived: sum of 3 quarters · filed 2025-02-28 | $309.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-03-31 | $96.00K 10-Q · filed 2024-05-10 | $365.00K derived: sum of 2 quarters · filed 2025-02-28 | $359.00K derived: sum of 3 quarters · filed 2025-02-28 | $298.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $263.00K derived: sum of 2 quarters · filed 2025-02-28 | $202.00K derived: sum of 3 quarters · filed 2025-02-28 | $271.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$67.00K derived: sum of 2 quarters · filed 2023-11-09 | $2.00K 10-Q · filed 2023-11-09 | -$5.00K derived: sum of 4 quarters · filed 2024-03-27 |
| 2023-06-30 | -$61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $8.00K 10-Q · filed 2023-08-10 | $1.00K derived: sum of 3 quarters · filed 2024-03-27 | $8.00K derived: sum of 4 quarters · filed 2024-03-27 |
| 2023-03-31 | $69.00K 10-Q · filed 2023-05-11 | $62.00K derived: sum of 2 quarters · filed 2024-03-27 | $69.00K derived: sum of 3 quarters · filed 2024-03-27 | $68.00K derived: sum of 4 quarters · filed 2024-03-27 |
| 2022-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $0.00 derived: sum of 2 quarters · filed 2024-03-27 | -$1.00K derived: sum of 3 quarters · filed 2024-03-27 | $1.00K 10-K · filed 2024-03-27 |
| 2022-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $6.00K derived: sum of 2 quarters · filed 2022-11-09 | $8.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.00K 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | $2.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |